Integrated Filing — IndAS
General information about company
| Scrip Code |
524816 |
| NSE Symbol |
NATCOPHARM |
| MSEI Symbol |
NOTLISTED |
| ISIN |
INE987B01026 |
| Name of company |
NATCO PHARMA LIMITED |
| Type of company |
Main Board |
| Class of security |
Equity |
| Date of start of financial year |
01-04-2026 |
| Date of end of financial year |
31-03-2027 |
| Date of board meeting when results were approved |
14-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed
to the exchange |
06-08-2026 |
| Description of presentation currency |
INR |
| Level of rounding used in financial results |
Lakhs |
| Reporting Type |
Quarterly |
| Reporting Quarter |
First quarter |
| Nature of report standalone or consolidated |
Consolidated |
| Whether results are audited or unaudited for the quarter ended |
Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended |
|
| Segment Reporting |
Multi segment |
| Description of single segment |
|
| Start date and time of board meeting |
14-08-2026 12:15:00 |
| End date and time of board meeting |
14-08-2026 14:00:00 |
| Whether cash flow statement is applicable on company |
|
| Type of cash flow statement |
|
| Declaration of unmodified opinion or statement on impact of audit qualification |
Not applicable |
Financial Results Ind-AS
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-04-2026 |
01-04-2026 |
| B |
Date of end of reporting period |
30-06-2026 |
30-06-2026 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
| 1 |
Income |
|
Revenue from operations |
73,520.00 |
73,520.00 |
|
Other income |
5,920.00 |
5,920.00 |
|
Total income |
79,440.00 |
79,440.00 |
| 2 |
Expenses |
| (a) |
Cost of materials consumed |
15,780.00 |
15,780.00 |
| (b) |
Purchases of stock-in-trade |
2,780.00 |
2,780.00 |
| (c) |
Changes in inventories of finished goods,
work-in-progress and stock-in-trade |
(3,810.00) |
(3,810.00) |
| (d) |
Employee benefit expense |
17,930.00 |
17,930.00 |
| (e) |
Finance costs |
1,300.00 |
1,300.00 |
| (f) |
Depreciation, depletion and amortisation expense
|
4,710.00 |
4,710.00 |
| (f) |
Other Expenses |
| 1 |
Other expenses |
22,190.00 |
22,190.00 |
|
Total other expenses |
22,190.00 |
22,190.00 |
|
Total expenses |
60,880.00 |
60,880.00 |
| 3 |
Total profit before exceptional items and tax |
18,560.00 |
18,560.00 |
| 4 |
Exceptional items |
0.00 |
0.00 |
| 5 |
Total profit before tax |
18,560.00 |
18,560.00 |
| 6 |
Tax expense |
|
| 7 |
Current tax |
4,880.00 |
4,880.00 |
| 8 |
Deferred tax |
1,460.00 |
1,460.00 |
| 9 |
Total tax expenses |
6,340.00 |
6,340.00 |
| 10 |
Net movement in regulatory deferral account balances related to profit or loss and
the related deferred tax movement |
0.00 |
0.00 |
| 11 |
Net Profit Loss for the period from
continuing operations |
12,220.00 |
12,220.00 |
| 12 |
Profit (loss) from discontinued operations before tax |
0.00 |
0.00 |
| 13 |
Tax expense of discontinued operations |
0.00 |
0.00 |
| 14 |
Net profit (loss) from discontinued
operation after tax |
0.00 |
0.00 |
| 15 |
Share of profit (loss) of associates and joint ventures accounted for using equity
method |
8,430.00 |
8,430.00 |
| 16 |
Total profit (loss) for period |
20,650.00 |
20,650.00 |
| 17 |
Other comprehensive income net of taxes |
11,100.00 |
11,100.00 |
| 18 |
Total Comprehensive Income for the period |
31,750.00 |
31,750.00 |
| 19 |
Total profit or loss, attributable to
|
|
|
|
Profit or loss, attributable to owners of parent |
20,650.00 |
20,650.00 |
|
Total profit or loss, attributable to non-controlling interests |
0.00 |
0.00 |
| 20 |
Total Comprehensive income for the period attributable to |
|
|
|
Comprehensive income for the period attributable to owners of parent |
31,750.00 |
31,750.00 |
|
Total comprehensive income for the period attributable to owners of parent non-controlling
interests |
0.00 |
0.00 |
| 21 |
Details of equity share capital |
|
|
Paid-up equity share capital |
3,580.00 |
3,580.00 |
|
Face value of equity share capital |
2 |
2 |
| 27 |
Details of debt securities |
|
| 22 |
Reserves excluding revaluation reserve |
|
|
| 23 |
Earnings per share |
|
| i |
Earnings per equity share for continuing operations |
|
|
Basic earnings (loss) per share from continuing operations |
11.53 |
11.53 |
|
Diluted earnings (loss) per share from continuing operations |
11.53 |
11.53 |
| ii |
Earnings per equity share for discontinued operations |
|
|
Basic earnings (loss) per share from discontinued operations |
0 |
0 |
|
Diluted earnings (loss) per share from discontinued operations |
0 |
0 |
| ii |
Earnings per equity share |
|
|
Basic earnings (loss) per share from continuing
and discontinued operations |
11.53 |
11.53 |
|
Diluted earnings (loss) per share from
continuing and discontinued operations |
11.53 |
11.53 |
| 24 |
Debt equity ratio |
|
|
| 25 |
Debt service coverage ratio |
|
|
| 26 |
Interest service coverage ratio |
|
|
| 27 |
Disclosure of notes on financial results |
|
Remarks
Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Amount in (Lakhs)
| Particulars |
3 months/ 6 month ended (dd-mm-yyyy) |
Year to date figures for current period
ended (dd-mm-yyyy) |
| Date of start of reporting period |
01-04-2026 |
01-04-2026 |
| Date of end of reporting
period |
30-06-2026 |
30-06-2026 |
| Whether results are audited
or unaudited |
Unaudited |
Unaudited |
| Nature of report standalone or
consolidated |
Consolidated |
Consolidated |
| 1 |
Segment Revenue (Income) |
|
(net sale/income from each segment should
be disclosed) |
| 1 |
Pharmaceuticals |
69,440.00 |
69,440.00 |
| 2 |
Agro Chemicals |
4,080.00 |
4,080.00 |
|
Total Segment Revenue |
73,520.00 |
73,520.00 |
|
Less: Inter segment revenue |
0.00 |
0.00 |
|
Revenue from operations |
73,520.00 |
73,520.00 |
| 2 |
Segment Result |
|
Profit (+) / Loss (-) before tax and
interest from each segment |
| 1 |
Pharmaceuticals |
20,390.00 |
20,390.00 |
| 2 |
Agro Chemicals |
(530.00) |
(530.00) |
|
Total Profit before tax |
19,860.00 |
19,860.00 |
|
i. Finance cost |
1,300.00 |
1,300.00 |
|
ii. Other Unallocable Expenditure net off Unallocable income |
0.00 |
0.00 |
|
Profit before tax |
18,560.00 |
18,560.00 |
| 3 |
(Segment Asset - Segment Liabilities)
|
|
Segment Asset |
| 1 |
Pharmaceuticals |
9,90,030.00 |
9,90,030.00 |
| 2 |
Agro Chemicals |
31,270.00 |
31,270.00 |
|
Total Segment Asset |
10,21,300.00 |
10,21,300.00 |
|
Un-allocable Assets |
1,02,150.00 |
1,02,150.00 |
|
Net Segment Asset |
11,23,450.00 |
11,23,450.00 |
| 4 |
Segment Liabilities |
|
Segment Liabilities |
| 1 |
Pharmaceuticals |
1,48,570.00 |
1,48,570.00 |
| 2 |
Agro Chemicals |
7,380.00 |
7,380.00 |
|
Total Segment Liabilities |
1,55,950.00 |
1,55,950.00 |
|
Un-allocable Liabilities |
13,650.00 |
13,650.00 |
|
Net Segment Liabilities |
1,69,600.00 |
1,69,600.00 |
|
Disclosure of notes on segments |
|
Other Comprehensive Income
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-04-2026 |
01-04-2026 |
| B |
Date of end of reporting period |
30-06-2026 |
30-06-2026 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
|
Other comprehensive income [Abstract] |
|
| 1 |
Amount of items that will not be reclassified to profit and loss |
|
| 1 |
Remeasurement of defined benefit liability/(assest) |
10.00 |
10.00 |
| 2 |
Fair value changes of equity investments through OCI |
1,030.00 |
1,030.00 |
| 3 |
Tax impact on fair value changes on equity investments through OCI |
(150.00) |
(150.00) |
|
Total Amount of items that will not be reclassified to profit and loss |
890.00 |
|
| 2 |
Income tax relating to items that will not be reclassified to profit or loss |
0.00 |
0.00 |
| 3 |
Amount of items that will be reclassified to profit and loss |
|
| 1 |
Exchange differences on translating financial statements of foreign operations |
10,880.00 |
10,880.00 |
| 2 |
Share of OCI of associate (net of tax) |
(670.00) |
(670.00) |
|
Total Amount of items that will be reclassified to profit and loss |
10,210.00 |
|
| 4 |
Income tax relating to items that will be reclassified to profit or loss |
0.00 |
0.00 |
| 5 |
Total Other comprehensive income |
11,100.00 |
11,100.00 |